Sana Biotechnology (NASDAQ:SANA – Get Free Report) and Stoke Therapeutics (NASDAQ:STOK – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, institutional ownership and earnings.
Analyst Ratings
This is a summary of recent recommendations and price targets for Sana Biotechnology and Stoke Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sana Biotechnology | 1 | 1 | 7 | 0 | 2.67 |
| Stoke Therapeutics | 1 | 1 | 9 | 0 | 2.73 |
Sana Biotechnology presently has a consensus target price of $9.50, suggesting a potential upside of 202.55%. Stoke Therapeutics has a consensus target price of $41.83, suggesting a potential upside of 33.40%. Given Sana Biotechnology’s higher probable upside, equities research analysts plainly believe Sana Biotechnology is more favorable than Stoke Therapeutics.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Sana Biotechnology | N/A | -108.01% | -40.68% |
| Stoke Therapeutics | -529.20% | -48.84% | -42.27% |
Earnings and Valuation
This table compares Sana Biotechnology and Stoke Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sana Biotechnology | N/A | N/A | -$244.17 million | ($0.97) | -3.24 |
| Stoke Therapeutics | $184.42 million | 10.59 | -$6.89 million | ($2.81) | -11.16 |
Stoke Therapeutics has higher revenue and earnings than Sana Biotechnology. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
88.2% of Sana Biotechnology shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by insiders. Comparatively, 9.5% of Stoke Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Risk & Volatility
Sana Biotechnology has a beta of 2.17, suggesting that its share price is 117% more volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.
Summary
Sana Biotechnology beats Stoke Therapeutics on 8 of the 13 factors compared between the two stocks.
About Sana Biotechnology
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company’s product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin’s lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam’s proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
About Stoke Therapeutics
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
